Since QPCTL expression is closely related to cytokine and chemokine function and modulation of QPCTL synergized with anti-PD-L1 expands CD8+ T cells and limits tumor growth, targeting QPTCL constitutes an effective approach for myeloid cell-targeted cancer immunotherapy; it prevents monocyte migration across inflammatory conditions (22). Here, CD8A is linked to neoplasm.